House Bill Would Stiffen Penalties for Drug Counterfeiters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

House Bill Would Stiffen Penalties for Drug Counterfeiters


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Nov. 17, 2011, a bill that would increase penalties for those convicted of trafficking in counterfeit drugs was introduced in the House of Representatives. The Counterfeit Drug Penalty Enhancement Act of 2011, cosponsored by Senators Patrick Leahy (D-VT), Chuck Grassley (R-IA), Michael Bennet (D-CO), and Richard Blumenthal (D-CT) and Representatives Patrick Meehan (R-PA) and Linda Sánchez (D-CA), would set maximum fines of $4 million for an individual and $10 million for a “person other than an individual,” and a maximum jail sentence of life imprisonment for an individual convicted of counterfeit drug trafficking.

Under current law, no distinction is made between counterfeit drugs and other counterfeit consumer items, such as clothing or electronics. The amendment is intended to address the severity of the crime and the potential for harm to the public. “These drugs present a serious threat to the health and safety of people around the world. It’s important we address this threat by imposing harsher penalties on criminals who counterfeit these medicines,” said Senator Grassley in a press release.

Pfizer issued a statement in support of the bill. The company has confirmed counterfeit versions of more than 50 of its medicines in at least 101 countries, according to the statement. Pfizer supports the tougher penalties, saying that they will afford patients greater safety. The proposed legislation “demonstrates that the US is prepared to lead in ensuring safety of the global drugs supply—both by putting a very tough anticounterfeiting law into effect in the world’s largest drugs market and by encouraging partner nations to put similar laws into effect,” according to the statement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here